Preliminary report on computed tomography radiomics features as biomarkers to immunotherapy selection in lung adenocarcinoma patients.

Vincenza Granata, Roberta Fusco, Matilde Costa, Carmine Picone, Diletta Cozzi, Chiara Moroni, Giorgia Viola La Casella, Agnese Montanino, Riccardo Monti, Francesca Mazzoni, Roberta Grassi, Valeria Grazia Malagnino, Salvatore Cappabianca, Roberto Grassi, Vittorio Miele, Antonella Petrillo

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: To assess the efficacy of radiomics features obtained by computed tomography (CT) examination as biomarkers in order to select patients with lung adenocarcinoma who would benefit from immunotherapy. Methods: Seventy-four patients (median age 63 years, range 42–86 years) with histologically confirmed lung cancer who underwent immunotherapy as first-or second-line therapy and who had baseline CT studies were enrolled in this approved retrospective study. As a control group, we selected 50 patients (median age 66 years, range 36–86 years) from 2005 to 2013 with histologically confirmed lung adenocarcinoma who underwent chemotherapy alone or in combination with targeted therapy. A total of 573 radiomic metrics were extracted: 14 features based on Hounsfield unit values specific for lung CT images; 66 first-order profile features based on intensity values; 43 second-order profile features based on lesion shape; 393 third-order profile features; and 57 features with higher-order profiles. Univariate and multivariate statistical analysis with pattern recognition approaches and the least absolute shrinkage and selection operator (LASSO) method were used to assess the capability of extracted radiomics features to predict overall survival (OS) and progression free survival (PFS) time. Results: A total of 38 patients (median age 61; range 41–78 years) with confirmed lung adenocarcinoma and subjected to immunotherapy satisfied inclusion criteria, and 50 patients in a control group were included in the analysis The shift in the center of mass of the lesion due to image intensity was significant both to predict OS in patients subjected to immunotherapy and to predict PFS in patients subjected to immunotherapy and in patients in the control group. With univariate analysis, low diagnostic accuracy was reached to stratify patients based on OS and PFS time. Regarding multivariate analysis, considering the robust (two morphological features, three textural features and three higher-order statistical metrics) application of the LASSO approach and all patients, a support vector machine reached the best results for stratifying patients based on OS (area under curve (AUC) of 0.89 and accuracy of 81.6%). Alternatively, considering the robust predictors (six textural features and one higher-order statistical metric) and application of the LASSO approach including all patients, a decision tree reached the best results for stratifying patients based on PFS time (AUC of 0.96 and accuracy of 94.7%). Conclusions: Specific radiomic features could be used to select patients with lung adenocarcinoma who would benefit from immunotherapy because a subset of imaging radiomic features useful to predict OS or PFS time were different between the control group and the immunotherapy group.

Original languageEnglish
Article number3992
JournalCancers
Volume13
Issue number16
DOIs
Publication statusPublished - Aug 7 2021

Keywords

  • Computed tomography
  • Lung adenocarcinoma
  • Morphological analysis
  • Radiomics
  • Texture analysis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Preliminary report on computed tomography radiomics features as biomarkers to immunotherapy selection in lung adenocarcinoma patients.'. Together they form a unique fingerprint.

Cite this